1. Academic Validation
  2. IFN-α: A key therapeutic target for multiple autoimmune rheumatic diseases

IFN-α: A key therapeutic target for multiple autoimmune rheumatic diseases

  • Drug Discov Today. 2021 Oct;26(10):2465-2473. doi: 10.1016/j.drudis.2021.06.010.
Frédéric De Ceuninck 1 Fanny Duguet 2 Audrey Aussy 3 Laurence Laigle 3 Philippe Moingeon 4
Affiliations

Affiliations

  • 1 Immuno-inflammatory Disease Department, Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy sur Seine, France. Electronic address: frederic.deceuninck@servier.com.
  • 2 Immuno-inflammatory Disease Department, Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy sur Seine, France.
  • 3 Immuno-inflammatory Disease Department, Institut de Recherches Servier, 50 rue Carnot, 92150 Suresnes, France.
  • 4 Immuno-inflammatory Disease Department, Institut de Recherches Servier, 50 rue Carnot, 92150 Suresnes, France; Immuno-inflammatory Disease Department, Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy sur Seine, France.
Abstract

Interferon (IFN)-α has emerged as a major therapeutic target for several autoimmune rheumatic diseases. In this review, we focus on clinical and preclinical advances in anti-IFN-α treatments in systemic lupus erythematosus (SLE), primary Sjögren syndrome (pSS), systemic sclerosis (SSc), and dermatomyositis (DM), for which a high medical need persists. Promising achievements were obtained following direct IFN-α neutralization, targeting its production through the cytosolic nucleic acid sensor pathways or by blocking its downstream effects through the type I IFN receptor. We further focus on molecular profiling and data integration approaches as crucial steps to select patients most likely to benefit from anti-IFN-α therapies within a precision medicine approach.

Keywords

Autoimmune rheumatic diseases; Dermatomyositis; Interferon gene signature; Interferon-alpha; Precision medicine; Primary Sjögren syndrome; Systemic lupus erythematosus; Systemic sclerosis; Therapy; Treatment.

Figures